Albumin binding drug conjugate companion diagnostic - LadRx Corporation
Alternative Names: 111In-C4-DTPA; ACDx - LadRx Corporation; Albumin conjugate diagnostic - LadRx CorporationLatest Information Update: 29 Sep 2022
At a glance
- Originator Centurion BioPharma
- Developer LadRx Corporation
- Class Diagnostic agents; Radiopharmaceutical diagnostics
- Mechanism of Action Radionuclide imaging enhancers; Single-photon emission-computed tomography enhancers
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- No development reported Liver cancer; Non-small cell lung cancer; Ovarian cancer; Pancreatic cancer
Most Recent Events
- 23 Sep 2022 CytRx Corporation is now called LadRx Corporation
- 28 Aug 2022 No recent reports of development identified for preclinical development in Liver-cancer(Diagnosis) in USA (Parenteral, Injection)
- 28 Aug 2022 No recent reports of development identified for preclinical development in Non-small-cell-lung-cancer(Diagnosis) in USA (Parenteral, Injection)